Zenith Technologies, a world leader in delivering GMP manufacturing software solutions to the life sciences industry, recently conducted an industry survey that suggests the digitalisation of manufacturing is a top priority.
The company conducted a survey of business and operational leaders across the life science sector on the trends and technologies that may revolutionise the industry over the coming years.
The research suggested an increasing appetite for Industry 4.0 – which focuses on using data and information to revolutionise GMP manufacturing.
Nearly 60% of those surveyed believe that Industry 4.0 will drive the most change in life science over the next 5 years, with 75% of those aiming to invest in people to take advantage of emerging technologies.
It also uncovered the main motivators for technology investment were cost and time saving, with more than 70 % of respondents citing these reasons.
Following on from these findings, Zenith published a whitepaper ‘Industry 4.0: Revolutionising life science manufacturing through connected systems and data’ written by global services director, David Staunton and MES project manager, Ryan McInerney.
The paper examines technological advances that are driving the next phase of pharmaceutical manufacturing, improving quality and reducing waste.
David Staunton said: “The life science industry has used data and information to drive improvements in GMP Manufacturing for decades and there is now an opportunity to take it to the next level.”
“The foundation of life science GMP manufacturing is to know your process and industry 4.0 allows us to stay true to who we are, while at the same time revolutionising GMP manufacturing.”
Founded in 1998, Zenith has 16 offices worldwide with over 800 skilled employees delivering manufacturing software to the life sciences industry in areas such as automation, Manufacturing Execution Systems (MES) and digital and data analysis. Zenith is a world leader in delivering GMP manufacturing software systems that secure the supply of vital medicines to patients worldwide.